![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Anzahl der Publikationen: 36
2020
Oberbeck, S.; Schrader, A.; Warner, K.; Jungherz, D.; Crispatzu, G.; von Jan, J.; Chmielewski, M.; Ianevski, A.; Diebner, H. H.; Mayer, P.; Ados, A. Kondo; Wahnschaffe, L.; Braun, T.; Müller, T. A.; Wagle, P.; Bouska, A.; Neumann, T.; Puetzer, S.; Varghese, L.; Pflug, N.; Thelen, M.; Makalowski, J.; Riet, N.; Goex, H. J. M.; Rappl, G.; Altmueller, J.; Kotrova, M.; Persigehl, T.; Hopfinger, G.; Hansmann, M. L.; Schloesser, H.; Stilgenbauer, S.; Duerig, J.; Mougiakakos, D.; Bergwelt-Baildon, M. von; Roeder, I; Hartmann, S.; Hallek, M.; Moriggl, R.; Brueggemann, M.; Aittokallio, T.; Iqbal, J.; Newrzela, S.; Abken, H. und Herling, M.
(2020):
Noncanonical effector functions of the T-memory-like T-PLL cell are shaped by cooperative TCL1A and TCR signaling.
In: Blood, Bd. 136, Nr. 24: S. 2786-2802
Al-Sawaf, O.; Robrecht, S.; Bahlo, J.; Fink, A. M.; Cramer, P.; Tresckow, J. von; Lange, E.; Kiehl, M.; Dreyling, M.; Ritgen, M.; Duerig, J.; Tausch, E.; Schneider, C.; Stilgenbauer, S.; Wendtner, C. M.; Fischer, K.; Goede, V.; Hallek, M. und Eichhorst, B.
(2020):
Richter transformation in chronic lymphocytic leukemia (CLL)-a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials.
In: Leukemia, Bd. 35, Nr. 1: S. 169-176
2017
Cramer, P.; Tresckow, J. von; Bahlo, J.; Robrecht, S.; Al-Sawaf, O.; Langerbeins, P.; Engelke, A.; Fink, A.-M.; Fischer, K.; Tausch, E.; Seiler, T.; Fischer von Weikersthal, L.; Hebart, H.; Kreuzer, K.-A.; Ritgen, M.; Kneba, M.; Wendtner, C.-M.; Stilgenbauer, S.; Eichhorst, B. und Hallek, M.
(2017):
Bendamustine (B), followed by obinutuzumab (G) and venetoclax (A) in patients with chronic lymphocytic leukemia (CLL): CLL2-BAG trial of the German CLL Study Group (GCLLSG).
In: Oncology Research and Treatment, Bd. 40: S. 24
Al-Sawaf, O.; Robrecht, S.; Bahlo, J.; Fink, A. M.; Cramer, P.; Tresckow, J. von; Maurer, C.; Bergmann, M.; Seiler, T.; Lange, E.; Kneba, M.; Stilgenbauer, S.; Döhner, H.; Kiehl, M. G.; Jäger, U.; Wendtner, C. M.; Fischer, K.; Göde, V.; Hallek, M.; Eichhorst, B. und Hopfinger, G.
(2017):
Impact of gender on outcome after chemoimmunotherapy in patients with chronic lymphocytic leukemia: a meta-analysis by the German CLL study group.
In: Leukemia, Bd. 31, Nr. 10: S. 2251-2253
Jerkeman, M.; Hallek, M.; Dreyling, M.; Thieblemont, C.; Kimby, E. und Staudt, L.
(2017):
Targeting of B-cell receptor signalling in B-cell malignancies.
In: Journal of internal Medicine, Bd. 282, Nr. 5: S. 415-428
Cramer, P.; Tresckow, J. von; Bahlo, J.; Robrecht, S.; Al Sawaf, O.; Langerbeins, P.; Engelke, A.; Fink, A.-M.; Fischer, K.; Seiler, T.; Fischer von Weikersthal, L.; Hebart, H.; Kreuzer, K.-A.; Ritgen, M.; Kneba, M.; Wendtner, C.-M.; Stilgenbauer, S.; Eichhorst, B. und Hallek, M.
(2017):
BENDAMUSTINE (B), followed by OBINUTUZUMAB (G, GA101) and VENETOCLAX (A, ABT-199) in patients with chronic lymphocytic leukemia (CLL): CLL2-BAG PHASE-II-TRIAL of the German CLL Study Group (GCLLSG).
In: Hämatologica, Bd. 102: S. 171-172
Pfreundschuh, M.; Christofyllakis, K.; Altmann, B.; Ziepert, M.; Haenel, M.; Viardot, A.; Neubauer, A.; Held, G.; Truemper, L.; Schmidt, C.; Kanz, L.; Hallek, M.; Schmitz, N.; Heintges, T.; Koelbel, C.; Schneider, G.; Ruebe, C.; Hellwig, D.; Poeschel, V. und Murawski, N.
(2017):
Radiotherapy to bulky disease PET-negative after immunochemotherapy can be spared in elderly DLBCL patients: results of a planned interim analysis of the first 187 patients with bulky disease treated in the OPTIMAL > 60 study of the DSHNHL.
In: Oncology Research and Treatment, Bd. 40: S. 11
Murawski, N.; Amam, J.; Altmann, B.; Ziepert, M.; Haenel, M.; Viardot, A.; Neubauer, A.; Held, G.; Truemper, L.; Schmidt, C.; Kanz, L.; Hallek, M.; Schmitz, N.; Heintges, T.; Koelbel, C.; Poeschel, V. und Pfreundschuh, M.
(2017):
Anti-infective prophylaxis with aciclovir and cotrimoxazole significantly reduces the rate of infections and therapy-associated deaths in elderly patients with DLBCL undergoing R-CHOP immunochemotherapy.
In: Oncology Research and Treatment, Bd. 40: S. 11
2016
Bühler, A.; Wendtner, C.-M.; Kipps, T. J.; Rassenti, L.; Fraser, G. A. M.; Michallet, A.-S.; Hillmen, P.; Duerig, J.; Gregory, S. A.; Kalaycio, M.; Aurran-Schleinitz, T.; Trentin, L.; Gribben, J. G.; Chanan-Khan, A.; Purse, B.; Zhang, J.; Bedout, S. de; Mei, J.; Hallek, M. und Stilgenbauer, S.
(2016):
Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial.
In: Blood Cancer Journal, Bd. 6, e404
Hermine, Olivier; Hoster, Eva; Walewski, J.; Bosly, A.; Stilgenbauer, S.; Thieblemont, C.; Szymczyk, Michal; Bouabdallah, R.; Kneba, M.; Hallek, M.; Salles, G.; Feugier, P.; Ribrag, Vincent; Birkmann, J.; Forstpointner, R.; Haioun, C.; Hänel, M.; Casasnovas, R. O.; Finke, J.; Peter, N.; Bouabdallah, K.; Sebban, C.; Fischer, T.; Dührsen, U.; Metzner, B.; Maschmeyer, G.; Kanz, L.; Schmidt, C.; Delarue, R.; Brousse, N.; Klapper, Wolfram; Macintyre, E.; Delfau-Larue, M. H.; Pott, Christiane; Hiddemann, Wolfgang; Unterhalt, Michael und Dreyling, Martin
(2016):
Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network.
In: Lancet, Bd. 388, Nr. 10044: S. 565-575
Maurer, C.; Langerbeins, P.; Bahlo, J.; Cramer, P.; Fink, A. M.; Pflug, N.; Engelke, A.; Tresckow, J. von; Kovacs, G.; Stilgenbauer, S.; Wendtner, C.-M.; Müller, L.; Ritgen, M.; Seiler, T.; Fischer, K.; Hallek, M. und Eichhorst, B.
(2016):
Effect of first-line treatment on second primary malignancies and Richter's transformation in patients with CLL.
In: Leukemia, Bd. 30, Nr. 10: S. 2019-2025
Hoster, Eva; Rosenwald, Andreas; Berger, F.; Bernd, Heinz Wolfram; Hartmann, S.; Loddenkemper, Christoph; Barth, Thomas E. F.; Brousse, N.; Pileri, S.; Rymkiewicz, G.; Kodet, Roman; Stilgenbauer, S.; Forstpointner, R.; Thieblemont, C.; Hallek, M.; Coiffier, B.; Vehling-Kaiser, U.; Bouabdallah, R.; Kanz, L.; Pfreundschuh, M.; Schmidt, C.; Ribrag, Vincent; Hiddemann, Wolfgang; Unterhalt, Michael; Kluin-Nelemans, J. C.; Hermine, Olivier; Dreyling, Martin und Klapper, Wolfram
(2016):
Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network.
In: Journal of Clinical Oncology, Bd. 34, Nr. 12: S. 1386-1394
Malard, F.; Labopin, M.; Stuhler, G.; Bittenbring, J.; Ganser, A.; Tischer, J.; Michallet, M.; Kroeger, N.; Schmid, C.; Huynh, A.; Hallek, M.; Savani, B.; Mohty, M. und Nagler, A.
(2016):
Sequential intensified conditioning regimen allogeneic hematopoietic stem cell transplantation in adult patients with high-risk AML in complete remission: a survey from the ALWP of the EBMT.
In: Bone Marrow Transplantation, Bd. 51:
S11-S11
Gorkom, G. van; Gelder, M. van; Ziagkos, D.; Koster, L.; Koc, Y.; Lint, M. van; Ciceri, F.; Selleslag, D.; Blaise, D.; Foa, R.; Beelen, D.; Corradini, P.; Moreno, C.; Carlson, K.; Solano, C.; Müller, L. P.; Castagna, L.; Tischer, J.; Hilgendorf, I.; Hallek, M.; Bittenbring, J.; Theobald, M.; Schetelig, J. und Kroeger, N.
(2016):
Outcomes of mismatched related allogeneic stem cell transplantation for chronic lymphocytic leukemia: a retrospective study on behalf of the chronic malignancies working party of the EBMT.
In: Bone Marrow Transplantation, Bd. 51:
S293-S294
Estenfelder, S.; Tausch, E.; Huber, H.; Bloehdorn, J.; Cymbalista, F.; Leblond, V.; Delmer, A.; Ibach, S.; Choquet, S.; Dartigeas, C.; Cazin, B.; Tournilhac, O.; Pegourie, B.; Seiler, T.; Sökler, M.; Zirlik, K.; Alt, J.; Schetelig, J.; Hallek, M.; Dreger, P.; Döhner, H. und Stilgenbauer, S.
(2016):
Mutation analysis by targeted next generation sequencing in ultra high risk CLL patients treated within the CLL20 study.
In: Haematologica, Bd. 101: S. 228-229
Pohlen, M.; Braess, J.; Thudium, J.; Schmid, C.; Kochanek, M.; Kreuzer, K.-A.; Görlich, D.; Gerth, U.; Rhode, C.; Müller-Tidow, C.; Stelljes, M.; Büchner, T.; Schlimok, G.; Hallek, M.; Waltenberger, J.; Hiddemann, W.; Berdel, W. E.; Heilmeier, B. und Krug, U.
(2016):
Patients with acute myeloid leukemia admitted to intensive care units: Scores predicting outcome and post-ICU survival.
In: Oncology Research and Treatment, Bd. 39: S. 51
Al-Sawaf, O.; Kluth, S.; Bahlo, J.; Hopfinger, G.; Fink, A. M.; Cramer, P.; Maurer, C.; Bergmann, M.; Dreyling, M.; Lange, E.; Kneba, M.; Stilgenbauer, S.; Kiehl, M. G.; Jäger, U.; Wendtner, C. M.; Fischer, K.; Hallek, M. und Eichhorst, B.
(2016):
Impact of gender on outcome after chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab (FCR) or bendamustin plus R (BR) in CLL patients: a pooled analysis of the German CLL Study Group (GCLLSG).
In: Oncology Research and Treatment, Bd. 39: S. 212-213
2015
Hoster, Eva; Geisler, C. H.; Doorduijn, J.; van der Holt, B.; Walewski, J.; Bloehdorn, J.; Ribrag, Vincent; Salles, G.; Hallek, M.; Pott, Christiane; Szymczyk, Michal; Kolstad, A.; Laurell, A.; Raty, R.; Jerkeman, M.; Van’t Veer, M.; Kluin-Nelemans, J. C.; Klapper, Wolfram; Unterhalt, Michael; Dreyling, Martin und Hermine, Olivier
(2015):
Total body irradiation after high-dose cytarabine in mantle cell lymphoma: a comparison of Nordic MCL2, HOVON-45, and European MCL Younger trials.
In: Leukemia, Bd. 30, Nr. 6: S. 1428-1430
2012
Kluin-Nelemans, H. C.; Hoster, Eva; Hermine, Olivier; Walewski, J.; Trneny, Marek; Geisler, C. H.; Stilgenbauer, S.; Thieblemont, C.; Vehling-Kaiser, U.; Doorduijn, J. K.; Coiffier, B.; Forstpointner, R.; Tilly, H.; Kanz, L.; Feugier, P.; Szymczyk, Michal; Hallek, M.; Kremers, S.; Lepeu, G.; Sanhes, L.; Zijlstra, J. M.; Bouabdallah, R.; Lugtenburg, P. J.; Macro, M.; Pfreundschuh, M.; Prochazka, V.; Di Raimondo, F.; Ribrag, Vincent; Uppenkamp, M.; Andre, M.; Klapper, Wolfram; Hiddemann, Wolfgang; Unterhalt, Michael und Dreyling, Martin
(2012):
Treatment of older patients with mantle-cell lymphoma.
In: New England Journal of Medicine / NEJM, Bd. 367, Nr. 6: S. 520-531
2011
Hehlmann, R.; Grimwade, D.; Simonsson, B.; Apperley, J.; Baccarani, M.; Barbui, T.; Barosi, G.; Bassan, R.; Béné, M. C.; Berger, Ursula; Büchner, T.; Burnett, A.; Cross, N. C.; de Witte, T. J.; Dohner, H.; Dombret, H.; Einsele, H.; Engelich, G.; Foa, R.; Fonatsch, C.; Gökbuget, Nicola; Gluckman, E.; Gratwohl, A.; Guilhot, F.; Haferlach, C.; Haferlach, T.; Hallek, M.; Hasford, Joerg; Hochhaus, A.; Hoelzer, D.; Kiladjian, J. J.; Labar, B.; Ljungman, P.; Mansmann, Ulrich; Niederwieser, D. W.; Ossenkoppele, G.; Ribera, J. M.; Rieder, H.; Serve, H.; Schrotz-King, P.; Sanz, M. A. und Saußele, Susanne
(2011):
The European LeukemiaNet: achievements and perspectives.
In: Haematologica, Bd. 96, Nr. 1: S. 156-162
2006
Saußele, Susanne; Adam, K.; Hochhaus, A.; Béné, M. C.; Büchner, T.; Burnett, A.; Finazzi, G.; Fonatsch, C.; Gluckman, E.; Gökbuget, Nicola; Grimwade, D. J.; Haferlach, T.; Hallek, M.; Hasford, Joerg; Hoelzer, D.; Ljungman, P.; Niederwieser, D. W.; Serve, H.; Simonsson, B.; de Witte, T. J. und Hehlmann, R.
(2006):
Klinische Forschung im „European LeukemiaNet”.
In: Deutsche Medizinische Wochenschrift - DMW, Bd. 131, Nr. 43: S. 2423-2426
2004
Hehlmann, R.; Berger, U.; Aul, C.; Büchner, Th; Dohner, H.; Ehninger, G.; Ganser, A.; Gökbuget, Nicola; Hoelzer, D.; Überla, Karl; Gassmann, W.; Ludwig, W. D.; Rieder, H.; Kneba, M.; Hochhaus, A.; Reiter, A.; Hiddemann, W.; Ottmann, O. G.; Germing, U.; Adelhard, K.; Dugas, M.; Dirschedl, P.; Messerer, D.; Böhme, A.; Harrison-Neu, E.; Griesshammer, M.; Kienast, J.; Kolb, H. J.; Ho, A. D.; Hallek, M.; Neubauer, A.; Schlegelberger, B.; Niederwieser, D.; Heil, G.; Müller, T. und Hasford, Joerg
(2004):
The German competence network 'Acute and chronic leukemias'.
In: Leukemia, Bd. 18, Nr. 4: S. 665-669
Buning, H.; Braun-Falco, M. und Hallek, M.
(2004):
Progress in the use of adeno-associated viral vectors for gene therapy.
In: Cells Tissues Organs, Nr. 3: S. 139-150
[PDF, 396kB]
Hallek, M.; Bergmann, M. und Emmerich, B.
(2004):
Chronic lymphocytic leukaemia: Up-dated recommendations on diagnosis and treatment.
In: Onkologie, Nr. 1: S. 97-104
[PDF, 88kB]
1994
Adler, S.; Lang, S.; Langenmayer, Irmgard; Eibl-Eibesfeldt, B.; Rump, W.; Emmerich, B. und Hallek, M.
(1994):
Chronotherapy with 5-Fluorouracil and Folinic Acid in Advanced Colorectal Carcinoma. Results of a chronopharmacologic phase I trial.
In: Cancer, Bd. 73, Nr. 12: S. 2905-2912
[PDF, 773kB]
1993
Hallek, M.; Levi, F.; Langenmayer, Irmgard; Kammermeier, I. und Emmerich, B.
(1993):
Chronopharmacology of mitoxantrone (MX): Evodence for a circadian rhythm of its myelotoxicity from an animal model and a clinical pilot trial.
In: Annals of Hematology, Supplements, Bd. 67, Nr. 45a
[PDF, 146kB]
Adler, S.; Lang, S.; Langenmayer, Irmgard; Eibl-Eibesfeldt, B.; Rump, W.; Emmerich, B. und Hallek, M.
(1993):
Chronotherapy with 5-Fluorouracil (5-FU) and folinic acid (FA) in advanced colorectal carcinoma: Results of a chronopharmacologic phase I/II trial.
In: Annals of Hematology, Supplements, Bd. 67, Nr. 1a
[PDF, 142kB]
1988
Haen, E.; Langenmayer, Irmgard; Emslander, H.-P.; Heusinger, H.; Hallek, M. und Remien, J.
(1988):
Effect of unequal twice daily theophylline on the circadian variation in the expression of ß2-adrenoceptor on peripheral mononuclear leucocytes.
In: Annual Review of Chronopharmacology, Bd. 5: S. 171-174
[PDF, 1MB]
Reithmann, C.; Arbogast, Helmut; Hallek, M. und Szinicz, L.
(1988):
Studies on the rare of central catecholaminergic mechanisms in the antidotal effect of the oxime HI 6 in soman poisoned mice.
In: Archives of toxicology, Bd. 62: S. 41-44
[PDF, 1MB]
Haen, E.; Lederer, T.; Rieber, P.; Schleicher, P.; Langenmayer, Irmgard; Hallek, M. und Remien, J.
(1988):
Does the circadian variation of ß2-adrenoceptor sites on peripheral mononuclear leukocytes (MNL) reflect the circadian variation of different MNL subsets.
In: Annual Review of Chronopharmacology, Bd. 5: S. 441-444
[PDF, 1MB]
1987
Arbogast, Helmut; Hallek, M.; Arbogast, B. und Szinicz, L.
(1987):
Circadian variation of the atropine effect on the running performance of mice treated with 1,2,2-trimethylpropylmethylphosphonofluoridate (soman).
2. annual meeting of the European Society for Chronobiology, Marburg, 1986.
Hildebrandt, Gunther (Hrsg.):
In: Chronobiology and chronomedicine,
S. 270-276
[PDF, 969kB]
1985
Arbogast, Helmut; Hallek, M.; Arbogast, B. und Szinicz, L.
(1985):
Circadian variation of the atropine effect on the running performance of mice treated with 1,2,2-trimethylpropylmethylphosphonofluoridate (soman).
In: Journal of interdisciplinary cycle research, Bd. 16: S. 241
[PDF, 249kB]
1984
Hallek, M.; Arbogast, B.; Hellbrügge, T.; Schmid, R.; Arbogast, Helmut und Kleiser, B.
(1984):
Circadian dysrhythmia in the behavior of children with clonazepam treatment.
1. Montreux Conference of Chronopharmacology, Montreux, 26. - 30. March 1984.
Reinberg, Alain (Hrsg.):
In: Biological rhythms and medications, Annual review of chronopharmacology
Bd. 1
S. 110
Arbogast, B.; Arbogast, Helmut; Halberg, F.; Hallek, M. und Hellbrügge, T.
(1984):
The chronobiology of the EEG and methods for analysis in health and convulsive disorder.
In: Chronobiologia, Bd. 11, Nr. 4: S. 396
[PDF, 124kB]
Hallek, M.; Arbogast, B.; Hellbrügge, T.; Schmid, R.; Arbogast, Helmut und Kleiser, B.
(1984):
Circadian dysrythmia in the behavior of epileptic children with clonazepam and/or phenobarbital treatment.
In: Annual review of chronopharmacology, Bd. 1: S. 37-40
[PDF, 1MB]
Arbogast, B.; Hallek, M.; Arbogast, Helmut; Hellbrügge, T. und Schmid, R.
(1984):
Ciradian dysrhythmias in the EEG of children with clonazepam treatment.
In: Annual review of chronopharmacology, Bd. 1: S. 17-20
[PDF, 325kB]